Abbott Laboratories ( (ABT) ) has released its Q1 earnings. Here is a breakdown of the information Abbott Laboratories presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbott Laboratories is a global healthcare company that specializes in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries. In its first-quarter 2025 earnings report, Abbott Laboratories reported a 4.0% increase in sales on a reported basis and 6.9% on an organic basis, with adjusted diluted EPS of $1.09, reflecting double-digit growth. The company also reaffirmed its full-year 2025 financial guidance.
Key financial highlights include a reported gross margin of 52.8% and an adjusted gross margin of 57.1%, with an adjusted operating margin of 21.0%. Abbott’s Medical Devices segment saw a 9.9% increase in sales, driven by strong performance in Diabetes Care and Structural Heart. The Nutrition segment reported a 3.8% increase in sales, led by the growth of Ensure and Glucerna brands.
Strategically, Abbott obtained CE Mark for its Volt PFA System in Europe and initiated a U.S. trial for its Coronary Intravascular Lithotripsy System. The company also announced new manufacturing and R&D investments in Illinois and Texas totaling $0.5 billion.
Looking ahead, Abbott projects full-year 2025 organic sales growth between 7.5% and 8.5% and adjusted diluted EPS between $5.05 and $5.25. The company remains committed to its diversified business model to sustain growth amidst market uncertainties.